The global market for Non-injectable Insulin was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Non-injectable insulin refers to a class of medications used to treat diabetes that do not need to be administered by injection. These medications are usually given orally or by other non-injectable routes to help control blood sugar levels and reduce or delay the onset of diabetes-related complications.

People with diabetes rely on insulin to control their blood glucose levels. This drug regulates and controls blood glucose levels by injected subcutaneously. A report from 2022 indicated that diabetes drugs around the world generated revenue of $78 billion. Since insulin is the preferred drug of choice for most diabetics, nasal or oral insulin intake provides comfort as an effective alternative to all other diabetes drugs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Non-injectable Insulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-injectable Insulin.

The Non-injectable Insulin market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-injectable Insulin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Non-injectable Insulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Non-injectable Insulin Market Report

Report Metric	Details
Report Name	Non-injectable Insulin Market
Segment by Type	Oral Pills Sprays Others
Segment by Application	T1DM T2DM
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Novo Nordisk, Sanofi, Eli Lilly, MannKind Corporation, Biocon, Janssen Pharmaceuticals, Adocia, Oramed Pharmaceuticals, Aerami Therapeutics, Medtronic, Verily Life Sciences, Larimar Therapeutics, Senseonics, Bigfoot Biomedical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Non-injectable Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Non-injectable Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Non-injectable Insulin Market report?

Ans: The main players in the Non-injectable Insulin Market are Novo Nordisk, Sanofi, Eli Lilly, MannKind Corporation, Biocon, Janssen Pharmaceuticals, Adocia, Oramed Pharmaceuticals, Aerami Therapeutics, Medtronic, Verily Life Sciences, Larimar Therapeutics, Senseonics, Bigfoot Biomedical

What are the Application segmentation covered in the Non-injectable Insulin Market report?

Ans: The Applications covered in the Non-injectable Insulin Market report are T1DM, T2DM

What are the Type segmentation covered in the Non-injectable Insulin Market report?

Ans: The Types covered in the Non-injectable Insulin Market report are Oral Pills, Sprays, Others

1 Non-injectable Insulin Market Overview

1.1 Product Definition

1.2 Non-injectable Insulin by Type

1.2.1 Global Non-injectable Insulin Market Value Comparison by Type (2024 VS 2031)

1.2.2 Oral Pills

1.2.3 Sprays

1.2.4 Others

1.3 Non-injectable Insulin by Application

1.3.1 Global Non-injectable Insulin Market Value by Application (2024 VS 2031)

1.3.2 T1DM

1.3.3 T2DM

1.4 Global Non-injectable Insulin Market Size Estimates and Forecasts

1.4.1 Global Non-injectable Insulin Revenue 2020-2031

1.4.2 Global Non-injectable Insulin Sales 2020-2031

1.4.3 Global Non-injectable Insulin Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Non-injectable Insulin Market Competition by Manufacturers

2.1 Global Non-injectable Insulin Sales Market Share by Manufacturers (2020-2025)

2.2 Global Non-injectable Insulin Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Non-injectable Insulin Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Non-injectable Insulin, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Non-injectable Insulin, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Non-injectable Insulin, Product Type & Application

2.7 Global Key Manufacturers of Non-injectable Insulin, Date of Enter into This Industry

2.8 Global Non-injectable Insulin Market Competitive Situation and Trends

2.8.1 Global Non-injectable Insulin Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Non-injectable Insulin Players Market Share by Revenue

2.8.3 Global Non-injectable Insulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Non-injectable Insulin Market Scenario by Region

3.1 Global Non-injectable Insulin Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Non-injectable Insulin Sales by Region: 2020-2031

3.2.1 Global Non-injectable Insulin Sales by Region: 2020-2025

3.2.2 Global Non-injectable Insulin Sales by Region: 2026-2031

3.3 Global Non-injectable Insulin Revenue by Region: 2020-2031

3.3.1 Global Non-injectable Insulin Revenue by Region: 2020-2025

3.3.2 Global Non-injectable Insulin Revenue by Region: 2026-2031

3.4 North America Non-injectable Insulin Market Facts & Figures by Country

3.4.1 North America Non-injectable Insulin Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Non-injectable Insulin Sales by Country (2020-2031)

3.4.3 North America Non-injectable Insulin Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Non-injectable Insulin Market Facts & Figures by Country

3.5.1 Europe Non-injectable Insulin Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Non-injectable Insulin Sales by Country (2020-2031)

3.5.3 Europe Non-injectable Insulin Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Non-injectable Insulin Market Facts & Figures by Region

3.6.1 Asia Pacific Non-injectable Insulin Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Non-injectable Insulin Sales by Region (2020-2031)

3.6.3 Asia Pacific Non-injectable Insulin Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Non-injectable Insulin Market Facts & Figures by Country

3.7.1 Latin America Non-injectable Insulin Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Non-injectable Insulin Sales by Country (2020-2031)

3.7.3 Latin America Non-injectable Insulin Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Non-injectable Insulin Market Facts & Figures by Country

3.8.1 Middle East and Africa Non-injectable Insulin Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Non-injectable Insulin Sales by Country (2020-2031)

3.8.3 Middle East and Africa Non-injectable Insulin Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Non-injectable Insulin Sales by Type (2020-2031)

4.1.1 Global Non-injectable Insulin Sales by Type (2020-2025)

4.1.2 Global Non-injectable Insulin Sales by Type (2026-2031)

4.1.3 Global Non-injectable Insulin Sales Market Share by Type (2020-2031)

4.2 Global Non-injectable Insulin Revenue by Type (2020-2031)

4.2.1 Global Non-injectable Insulin Revenue by Type (2020-2025)

4.2.2 Global Non-injectable Insulin Revenue by Type (2026-2031)

4.2.3 Global Non-injectable Insulin Revenue Market Share by Type (2020-2031)

4.3 Global Non-injectable Insulin Price by Type (2020-2031)

5 Segment by Application

5.1 Global Non-injectable Insulin Sales by Application (2020-2031)

5.1.1 Global Non-injectable Insulin Sales by Application (2020-2025)

5.1.2 Global Non-injectable Insulin Sales by Application (2026-2031)

5.1.3 Global Non-injectable Insulin Sales Market Share by Application (2020-2031)

5.2 Global Non-injectable Insulin Revenue by Application (2020-2031)

5.2.1 Global Non-injectable Insulin Revenue by Application (2020-2025)

5.2.2 Global Non-injectable Insulin Revenue by Application (2026-2031)

5.2.3 Global Non-injectable Insulin Revenue Market Share by Application (2020-2031)

5.3 Global Non-injectable Insulin Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Novo Nordisk

6.1.1 Novo Nordisk Company Information

6.1.2 Novo Nordisk Description and Business Overview

6.1.3 Novo Nordisk Non-injectable Insulin Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Novo Nordisk Non-injectable Insulin Product Portfolio

6.1.5 Novo Nordisk Recent Developments/Updates

6.2 Sanofi

6.2.1 Sanofi Company Information

6.2.2 Sanofi Description and Business Overview

6.2.3 Sanofi Non-injectable Insulin Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Sanofi Non-injectable Insulin Product Portfolio

6.2.5 Sanofi Recent Developments/Updates

6.3 Eli Lilly

6.3.1 Eli Lilly Company Information

6.3.2 Eli Lilly Description and Business Overview

6.3.3 Eli Lilly Non-injectable Insulin Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Eli Lilly Non-injectable Insulin Product Portfolio

6.3.5 Eli Lilly Recent Developments/Updates

6.4 MannKind Corporation

6.4.1 MannKind Corporation Company Information

6.4.2 MannKind Corporation Description and Business Overview

6.4.3 MannKind Corporation Non-injectable Insulin Sales, Revenue and Gross Margin (2020-2025)

6.4.4 MannKind Corporation Non-injectable Insulin Product Portfolio

6.4.5 MannKind Corporation Recent Developments/Updates

6.5 Biocon

6.5.1 Biocon Company Information

6.5.2 Biocon Description and Business Overview

6.5.3 Biocon Non-injectable Insulin Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Biocon Non-injectable Insulin Product Portfolio

6.5.5 Biocon Recent Developments/Updates

6.6 Janssen Pharmaceuticals

6.6.1 Janssen Pharmaceuticals Company Information

6.6.2 Janssen Pharmaceuticals Description and Business Overview

6.6.3 Janssen Pharmaceuticals Non-injectable Insulin Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Janssen Pharmaceuticals Non-injectable Insulin Product Portfolio

6.6.5 Janssen Pharmaceuticals Recent Developments/Updates

6.7 Adocia

6.7.1 Adocia Company Information

6.7.2 Adocia Description and Business Overview

6.7.3 Adocia Non-injectable Insulin Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Adocia Non-injectable Insulin Product Portfolio

6.7.5 Adocia Recent Developments/Updates

6.8 Oramed Pharmaceuticals

6.8.1 Oramed Pharmaceuticals Company Information

6.8.2 Oramed Pharmaceuticals Description and Business Overview

6.8.3 Oramed Pharmaceuticals Non-injectable Insulin Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Oramed Pharmaceuticals Non-injectable Insulin Product Portfolio

6.8.5 Oramed Pharmaceuticals Recent Developments/Updates

6.9 Aerami Therapeutics

6.9.1 Aerami Therapeutics Company Information

6.9.2 Aerami Therapeutics Description and Business Overview

6.9.3 Aerami Therapeutics Non-injectable Insulin Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Aerami Therapeutics Non-injectable Insulin Product Portfolio

6.9.5 Aerami Therapeutics Recent Developments/Updates

6.10 Medtronic

6.10.1 Medtronic Company Information

6.10.2 Medtronic Description and Business Overview

6.10.3 Medtronic Non-injectable Insulin Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Medtronic Non-injectable Insulin Product Portfolio

6.10.5 Medtronic Recent Developments/Updates

6.11 Verily Life Sciences

6.11.1 Verily Life Sciences Company Information

6.11.2 Verily Life Sciences Description and Business Overview

6.11.3 Verily Life Sciences Non-injectable Insulin Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Verily Life Sciences Non-injectable Insulin Product Portfolio

6.11.5 Verily Life Sciences Recent Developments/Updates

6.12 Larimar Therapeutics

6.12.1 Larimar Therapeutics Company Information

6.12.2 Larimar Therapeutics Description and Business Overview

6.12.3 Larimar Therapeutics Non-injectable Insulin Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Larimar Therapeutics Non-injectable Insulin Product Portfolio

6.12.5 Larimar Therapeutics Recent Developments/Updates

6.13 Senseonics

6.13.1 Senseonics Company Information

6.13.2 Senseonics Description and Business Overview

6.13.3 Senseonics Non-injectable Insulin Sales, Revenue and Gross Margin (2020-2025)

6.13.4 Senseonics Non-injectable Insulin Product Portfolio

6.13.5 Senseonics Recent Developments/Updates

6.14 Bigfoot Biomedical

6.14.1 Bigfoot Biomedical Company Information

6.14.2 Bigfoot Biomedical Description and Business Overview

6.14.3 Bigfoot Biomedical Non-injectable Insulin Sales, Revenue and Gross Margin (2020-2025)

6.14.4 Bigfoot Biomedical Non-injectable Insulin Product Portfolio

6.14.5 Bigfoot Biomedical Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Non-injectable Insulin Industry Chain Analysis

7.2 Non-injectable Insulin Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Non-injectable Insulin Production Mode & Process Analysis

7.4 Non-injectable Insulin Sales and Marketing

7.4.1 Non-injectable Insulin Sales Channels

7.4.2 Non-injectable Insulin Distributors

7.5 Non-injectable Insulin Customer Analysis

8 Non-injectable Insulin Market Dynamics

8.1 Non-injectable Insulin Industry Trends

8.2 Non-injectable Insulin Market Drivers

8.3 Non-injectable Insulin Market Challenges

8.4 Non-injectable Insulin Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Janssen Pharmaceuticals

Adocia

Oramed Pharmaceuticals

List of Tables

Table 1. Global Non-injectable Insulin Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Non-injectable Insulin Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Non-injectable Insulin Market Competitive Situation by Manufacturers in 2024

Table 4. Global Non-injectable Insulin Sales (Units) of Key Manufacturers (2020-2025)

Table 5. Global Non-injectable Insulin Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Non-injectable Insulin Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Non-injectable Insulin Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Non-injectable Insulin Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Non-injectable Insulin, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Non-injectable Insulin, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Non-injectable Insulin, Product Type & Application

Table 12. Global Key Manufacturers of Non-injectable Insulin, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Non-injectable Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-injectable Insulin as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Non-injectable Insulin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Non-injectable Insulin Sales by Region (2020-2025) & (Units)

Table 18. Global Non-injectable Insulin Sales Market Share by Region (2020-2025)

Table 19. Global Non-injectable Insulin Sales by Region (2026-2031) & (Units)

Table 20. Global Non-injectable Insulin Sales Market Share by Region (2026-2031)

Table 21. Global Non-injectable Insulin Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Non-injectable Insulin Revenue Market Share by Region (2020-2025)

Table 23. Global Non-injectable Insulin Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Non-injectable Insulin Revenue Market Share by Region (2026-2031)

Table 25. North America Non-injectable Insulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Non-injectable Insulin Sales by Country (2020-2025) & (Units)

Table 27. North America Non-injectable Insulin Sales by Country (2026-2031) & (Units)

Table 28. North America Non-injectable Insulin Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Non-injectable Insulin Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Non-injectable Insulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Non-injectable Insulin Sales by Country (2020-2025) & (Units)

Table 32. Europe Non-injectable Insulin Sales by Country (2026-2031) & (Units)

Table 33. Europe Non-injectable Insulin Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Non-injectable Insulin Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Non-injectable Insulin Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Non-injectable Insulin Sales by Region (2020-2025) & (Units)

Table 37. Asia Pacific Non-injectable Insulin Sales by Region (2026-2031) & (Units)

Table 38. Asia Pacific Non-injectable Insulin Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Non-injectable Insulin Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Non-injectable Insulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Non-injectable Insulin Sales by Country (2020-2025) & (Units)

Table 42. Latin America Non-injectable Insulin Sales by Country (2026-2031) & (Units)

Table 43. Latin America Non-injectable Insulin Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Non-injectable Insulin Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Non-injectable Insulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Non-injectable Insulin Sales by Country (2020-2025) & (Units)

Table 47. Middle East and Africa Non-injectable Insulin Sales by Country (2026-2031) & (Units)

Table 48. Middle East and Africa Non-injectable Insulin Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Non-injectable Insulin Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Non-injectable Insulin Sales (Units) by Type (2020-2025)

Table 51. Global Non-injectable Insulin Sales (Units) by Type (2026-2031)

Table 52. Global Non-injectable Insulin Sales Market Share by Type (2020-2025)

Table 53. Global Non-injectable Insulin Sales Market Share by Type (2026-2031)

Table 54. Global Non-injectable Insulin Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Non-injectable Insulin Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Non-injectable Insulin Revenue Market Share by Type (2020-2025)

Table 57. Global Non-injectable Insulin Revenue Market Share by Type (2026-2031)

Table 58. Global Non-injectable Insulin Price (US$/Unit) by Type (2020-2025)

Table 59. Global Non-injectable Insulin Price (US$/Unit) by Type (2026-2031)

Table 60. Global Non-injectable Insulin Sales (Units) by Application (2020-2025)

Table 61. Global Non-injectable Insulin Sales (Units) by Application (2026-2031)

Table 62. Global Non-injectable Insulin Sales Market Share by Application (2020-2025)

Table 63. Global Non-injectable Insulin Sales Market Share by Application (2026-2031)

Table 64. Global Non-injectable Insulin Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Non-injectable Insulin Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Non-injectable Insulin Revenue Market Share by Application (2020-2025)

Table 67. Global Non-injectable Insulin Revenue Market Share by Application (2026-2031)

Table 68. Global Non-injectable Insulin Price (US$/Unit) by Application (2020-2025)

Table 69. Global Non-injectable Insulin Price (US$/Unit) by Application (2026-2031)

Table 70. Novo Nordisk Company Information

Table 71. Novo Nordisk Description and Business Overview

Table 72. Novo Nordisk Non-injectable Insulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Novo Nordisk Non-injectable Insulin Product

Table 74. Novo Nordisk Recent Developments/Updates

Table 75. Sanofi Company Information

Table 76. Sanofi Description and Business Overview

Table 77. Sanofi Non-injectable Insulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Sanofi Non-injectable Insulin Product

Table 79. Sanofi Recent Developments/Updates

Table 80. Eli Lilly Company Information

Table 81. Eli Lilly Description and Business Overview

Table 82. Eli Lilly Non-injectable Insulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Eli Lilly Non-injectable Insulin Product

Table 84. Eli Lilly Recent Developments/Updates

Table 85. MannKind Corporation Company Information

Table 86. MannKind Corporation Description and Business Overview

Table 87. MannKind Corporation Non-injectable Insulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. MannKind Corporation Non-injectable Insulin Product

Table 89. MannKind Corporation Recent Developments/Updates

Table 90. Biocon Company Information

Table 91. Biocon Description and Business Overview

Table 92. Biocon Non-injectable Insulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Biocon Non-injectable Insulin Product

Table 94. Biocon Recent Developments/Updates

Table 95. Janssen Pharmaceuticals Company Information

Table 96. Janssen Pharmaceuticals Description and Business Overview

Table 97. Janssen Pharmaceuticals Non-injectable Insulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Janssen Pharmaceuticals Non-injectable Insulin Product

Table 99. Janssen Pharmaceuticals Recent Developments/Updates

Table 100. Adocia Company Information

Table 101. Adocia Description and Business Overview

Table 102. Adocia Non-injectable Insulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Adocia Non-injectable Insulin Product

Table 104. Adocia Recent Developments/Updates

Table 105. Oramed Pharmaceuticals Company Information

Table 106. Oramed Pharmaceuticals Description and Business Overview

Table 107. Oramed Pharmaceuticals Non-injectable Insulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. Oramed Pharmaceuticals Non-injectable Insulin Product

Table 109. Oramed Pharmaceuticals Recent Developments/Updates

Table 110. Aerami Therapeutics Company Information

Table 111. Aerami Therapeutics Description and Business Overview

Table 112. Aerami Therapeutics Non-injectable Insulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. Aerami Therapeutics Non-injectable Insulin Product

Table 114. Aerami Therapeutics Recent Developments/Updates

Table 115. Medtronic Company Information

Table 116. Medtronic Description and Business Overview

Table 117. Medtronic Non-injectable Insulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 118. Medtronic Non-injectable Insulin Product

Table 119. Medtronic Recent Developments/Updates

Table 120. Verily Life Sciences Company Information

Table 121. Verily Life Sciences Description and Business Overview

Table 122. Verily Life Sciences Non-injectable Insulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 123. Verily Life Sciences Non-injectable Insulin Product

Table 124. Verily Life Sciences Recent Developments/Updates

Table 125. Larimar Therapeutics Company Information

Table 126. Larimar Therapeutics Description and Business Overview

Table 127. Larimar Therapeutics Non-injectable Insulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 128. Larimar Therapeutics Non-injectable Insulin Product

Table 129. Larimar Therapeutics Recent Developments/Updates

Table 130. Senseonics Company Information

Table 131. Senseonics Description and Business Overview

Table 132. Senseonics Non-injectable Insulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 133. Senseonics Non-injectable Insulin Product

Table 134. Senseonics Recent Developments/Updates

Table 135. Bigfoot Biomedical Company Information

Table 136. Bigfoot Biomedical Description and Business Overview

Table 137. Bigfoot Biomedical Non-injectable Insulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 138. Bigfoot Biomedical Non-injectable Insulin Product

Table 139. Bigfoot Biomedical Recent Developments/Updates

Table 140. Key Raw Materials Lists

Table 141. Raw Materials Key Suppliers Lists

Table 142. Non-injectable Insulin Distributors List

Table 143. Non-injectable Insulin Customers List

Table 144. Non-injectable Insulin Market Trends

Table 145. Non-injectable Insulin Market Drivers

Table 146. Non-injectable Insulin Market Challenges

Table 147. Non-injectable Insulin Market Restraints

Table 148. Research Programs/Design for This Report

Table 149. Key Data Information from Secondary Sources

Table 150. Key Data Information from Primary Sources

Table 151. Authors List of This Report

List of Figures

Figure 1. Product Picture of Non-injectable Insulin

Figure 2. Global Non-injectable Insulin Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Non-injectable Insulin Market Share by Type: 2024 & 2031

Figure 4. Oral Pills Product Picture

Figure 5. Sprays Product Picture

Figure 6. Others Product Picture

Figure 7. Global Non-injectable Insulin Market Value by Application (2020-2031) & (US$ Million)

Figure 8. Global Non-injectable Insulin Market Share by Application: 2024 & 2031

Figure 9. T1DM

Figure 10. T2DM

Figure 11. Global Non-injectable Insulin Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global Non-injectable Insulin Market Size (2020-2031) & (US$ Million)

Figure 13. Global Non-injectable Insulin Sales (2020-2031) & (Units)

Figure 14. Global Non-injectable Insulin Average Price (US$/Unit) & (2020-2031)

Figure 15. Non-injectable Insulin Report Years Considered

Figure 16. Non-injectable Insulin Sales Share by Manufacturers in 2024

Figure 17. Global Non-injectable Insulin Revenue Share by Manufacturers in 2024

Figure 18. Global 5 and 10 Largest Non-injectable Insulin Players: Market Share by Revenue in Non-injectable Insulin in 2024

Figure 19. Non-injectable Insulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 20. Global Non-injectable Insulin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 21. North America Non-injectable Insulin Sales Market Share by Country (2020-2031)

Figure 22. North America Non-injectable Insulin Revenue Market Share by Country (2020-2031)

Figure 23. United States Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 24. Canada Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Europe Non-injectable Insulin Sales Market Share by Country (2020-2031)

Figure 26. Europe Non-injectable Insulin Revenue Market Share by Country (2020-2031)

Figure 27. Germany Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. France Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. U.K. Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Italy Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Russia Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Asia Pacific Non-injectable Insulin Sales Market Share by Region (2020-2031)

Figure 33. Asia Pacific Non-injectable Insulin Revenue Market Share by Region (2020-2031)

Figure 34. China Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Japan Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. South Korea Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. India Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Australia Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. China Taiwan Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Southeast Asia Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Latin America Non-injectable Insulin Sales Market Share by Country (2020-2031)

Figure 42. Latin America Non-injectable Insulin Revenue Market Share by Country (2020-2031)

Figure 43. Mexico Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Brazil Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Argentina Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Colombia Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Middle East and Africa Non-injectable Insulin Sales Market Share by Country (2020-2031)

Figure 48. Middle East and Africa Non-injectable Insulin Revenue Market Share by Country (2020-2031)

Figure 49. Turkey Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Saudi Arabia Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. UAE Non-injectable Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Global Sales Market Share of Non-injectable Insulin by Type (2020-2031)

Figure 53. Global Revenue Market Share of Non-injectable Insulin by Type (2020-2031)

Figure 54. Global Non-injectable Insulin Price (US$/Unit) by Type (2020-2031)

Figure 55. Global Sales Market Share of Non-injectable Insulin by Application (2020-2031)

Figure 56. Global Revenue Market Share of Non-injectable Insulin by Application (2020-2031)

Figure 57. Global Non-injectable Insulin Price (US$/Unit) by Application (2020-2031)

Figure 58. Non-injectable Insulin Value Chain

Figure 59. Channels of Distribution (Direct Vs Distribution)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions